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Abstract 
Background: For patients with nasopharyngeal carcinoma (NPC) who undergo re‑irradiation with intensity‑mod‑
ulated radiotherapy (IMRT), lethal nasopharyngeal necrosis (LNN) is a severe late adverse event. The purpose of this 
study was to identify risk factors for LNN and develop a model to predict LNN after radical re‑irradiation with IMRT in 
patients with recurrent NPC.
Methods: Patients who underwent radical re‑irradiation with IMRT for locally recurrent NPC between March 2001 
and December 2011 and who had no evidence of distant metastasis were included in this study. Clinical character‑
istics, including recurrent carcinoma conditions and dosimetric features, were evaluated as candidate risk factors for 
LNN. Logistic regression analysis was used to identify independent risk factors and construct the predictive scoring 
model.
Results: Among 228 patients enrolled in this study, 204 were at risk of developing LNN based on risk analy‑
sis. Of the 204 patients treated, 31 (15.2%) developed LNN. Logistic regression analysis showed that female sex 
(P = 0.008), necrosis before re‑irradiation (P = 0.008), accumulated total prescription dose to the gross tumor volume 
(GTV) ≥145.5 Gy (P = 0.043), and recurrent tumor volume ≥25.38 cm3 (P = 0.009) were independent risk factors for 
LNN. A model to predict LNN was then constructed that included these four independent risk factors.
Conclusions: A model that includes sex, necrosis before re‑irradiation, accumulated total prescription dose to GTV, 
and recurrent tumor volume can effectively predict the risk of developing LNN in NPC patients who undergo radical 
re‑irradiation with IMRT.
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Background
In South China, especially in Guangdong Province, naso-
pharyngeal carcinoma (NPC) is a common head and 
neck cancer [1, 2]. It is a highly radiosensitive malig-
nancy with a local recurrence rate of 10%–36% [3–5]. In 
the past several decades, various treatment modalities, 
including external-beam radiotherapy (EBRT), intracavi-
tary brachytherapy, interstitial radioactive implantation, 
stereotactic radiosurgery, nasopharyngectomy, chemo-
therapy, and a combination of these methods, have been 
used to treat the patients with NPC. Each method has 
its optimal treatment population [6]; for patients with 
locally recurrent NPC, EBRT remains the most effective 
modality [7].
Intensity-modulated radiotherapy (IMRT) is consid-
ered a better technique for the treatment of recurrent 
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NPC because of its lower normal tissue doses and more 
homogeneous target doses compared with conformal 
radiotherapy [8]. Currently, radical IMRT is the most 
effective treatment for patients with locally recurrent 
NPC. However, IMRT does carry a risk of late toxicities 
that should not be ignored. For patients re-irradiated 
with IMRT for recurrent NPC, the patients with irrevers-
ible nasopharyngeal necrosis have the largest proportion 
of reported severe late adverse events [9], which may 
result in massive nasopharyngeal hemorrhage and death. 
Therefore, for patients with recurrent NPC who have 
undergone re-irradiation, it is urgent to predict and avoid 
lethal nasopharyngeal necrosis (LNN). In this retrospec-
tive study, we examined the relationship between the 
clinical characteristics of re-irradiated NPC patients and 
the incidence of LNN, and we subsequently developed a 
predictive scoring model for LNN.
Patients and methods
Patient selection
Patients who underwent radical re-irradiation with 
IMRT for locally recurrent NPC between March 2001 
and December 2011 and who had no evidence of dis-
tant metastasis were included in this study. All patients 
had weekly nasopharyngeal examinations with nasopha-
ryngoscopy during IMRT treatment and were followed 
1 month after IMRT, every 3 months for the first 2 years, 
every 6 months for 3 additional years, and annually there-
after. Each follow-up included a complete medical record 
review, physical examination, and nasopharyngoscopy 
examination. At least once a year, if necessary, patients 
underwent serum electrolyte and complete blood count 
tests as well as chest X-ray, ultrasound/computed tomog-
raphy (CT) of the abdomen, and magnetic resonance 
imaging (MRI) of the head-and-neck region. This study 
was approved by the Ethics Committee of Sun Yat-sen 
University Cancer Center.
IMRT was conducted as previously reported [10, 11]. 
Patients were placed in a supine position on a custom-
made head support and immobilized with a thermo-
plastic mask covering the head and upper neck. CT 
scanning from the superior border of the frontal sinus 
to 2 cm below the clavicular heads was performed with 
a 3-mm slice thickness. Imaging data were transferred to 
the Corvus inverse treatment planning system (NOMOS 
Corporation, Wexford, PA, USA). The gross tumor vol-
ume (GTV), clinical target volume (CTV), gross tumor 
volume of cervical lymph node (GTVnd), and organs at 
risk (OARs) were contoured slice by slice on CT images. 
The recurrent gross target of the nasopharynx and lymph 
nodes in the neck were determined according to CT/
MRI and physical examinations. According to guidelines 
from the International Commission on Radiation Units 
and Measurements Report 62 (ICRU62) [12], CTV was 
defined as GTV plus a 0.5–1 cm margin; it also included 
the recurrent lymph nodes in the neck. OARs, includ-
ing the brainstem, spinal cord, temporal lobes, lens, 
optic nerves, chiasm, parotid glands, temporoman-
dibular joints, and mandible, were carefully contoured. 
Planning target volumes for GTV, GTVnd, and CTV 
were generated according to immobilization and locali-
zation uncertainties. According to our measurements, 
the immobilization uncertainty was 2  mm in the lateral 
direction and 1  mm in the anterior, posterior, superior, 
and inferior directions. Localization uncertainty was 
defined according to the involved organs’ mobility, which 
was 1–2  mm for both tumor targets and the surround-
ing normal tissues. The total uncertainty, as automati-
cally generated by the Corvus system, was 1.4–2.8  mm 
in every orientation. All patients received full-course 
IMRT with 6-MV X-rays generated by a Clinac-600C lin-
ear accelerator (Varian Medical Systems, Palo Alto, CA, 
USA). As a general rule, the dose comprising 33% of con-
tralateral OARs was limited to less than one-half of the 
tolerance dose, referring to a severe complication rate of 
5% within 5  years of radiotherapy (TD5/5). The dose of 
the ipsilateral side was not constrained as that of the con-
tralateral side. Dose verification was carried out before 
re-irradiation. The dose error between the measurement 
and the plan was less than 3%.
Diagnosis of nasopharyngeal necrosis
Diagnosis of nasopharyngeal necrosis was based on 
the clinical characteristics, including foul nasal smell, 
refractory headache, filemot necrotic tissue and skull 
base osteoradionecrosis in nasopharyngeal cavity under 
endoscopy, discontinuous nasopharyngeal mucosa line 
and/or tissue defects on MRI, and a heap of red-stained 
substance without cellular structure in hematoxylin-
eosin staining under pathologic examination [11, 13–19]. 
Patients who died from intractable epistaxis diagnosed 
with nasopharyngeal necrosis were recorded as having 
LNN.
Study parameters
Potential clinical characteristics, including sex, age, body 
mass index (BMI) at recurrence, recurrent stage, inter-
val of recurrence, concurrent chemotherapy during re-
irradiation, necrosis before re-irradiation, initial total 
radiation dose and fractionated dose, re-irradiation pre-
scription dose to the GTV, mean re-irradiation dose, re-
irradiation fractionated dose, duration of re-irradiation, 
accumulated total prescription dose to the GTV (ini-
tial and recurrent), and recurrent tumor volume, were 
recorded. The recurrent stage was reclassified accord-
ing to the 2009 American Joint Committee on Cancer 
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staging system. The interval of recurrence was defined 
from the last day of initial radiotherapy to the first day of 
re-irradiation. Necrosis before re-irradiation was defined 
as necrosis detected before the first day of re-irradiation. 
Duration of re-irradiation was calculated from the first 
day to the last day of re-irradiation.
Statistical methods
All statistical analyses were performed using SPSS 22.0 
software (SPSS, Chicago, IL, USA). Receiver operat-
ing characteristic curves based on LNN were applied to 
determine the cutoff points for the continuous variables. 
Logistic regression analysis was performed to estimate 
odds ratios (ORs) or adjusted odds ratios (AORs), 95% 
Confidence Intervals (CIs) and P values. Univariate logis-
tic regression analysis was performed to identify poten-
tial risk factors for LNN. Multivariate logistic regression 
analysis was performed to distinguish the independent 
risk factors for LNN from the variables with statistical 
significance in the univariate logistic regression analysis. 
Multivariate logistic regression analysis was also used to 
construct a predictive model for LNN. All statistical tests 




In total, 228 patients were included in this study; among 
these, 24 patients were excluded from further analy-
ses because the initial radiation dose was not available. 
Of the eligible 204 patients, 169 (82.8%) were diagnosed 
based on pathologic analysis with locally recurrent NPC; 
the remaining 35 (17.2%) were clinically diagnosed based 
on symptoms, MRI, or CT images. The median BMI of 
patients was 21.8 kg/m2 (range, 14.2–31.3 kg/m2), with a 
median age of 46 years (range, 21–79 years). All patients 
underwent conventional radiotherapy with 2  Gy/frac-
tion per day, 5 days every week, in the initial treatment; 
the median isocenter dose to the nasopharynx was 70 Gy 
(range, 56–83 Gy). The median interval of recurrence was 
30 months (range, 9–216 months). All patients completed 
the full-course radical IMRT of re-irradiation with the 
median re-irradiation prescription dose to the GTV of 
64 Gy (range, 58–70 Gy), 2.14 Gy (range, 1.88–2.33 Gy)/
fraction per day, 5  days every week. The duration of re-
irradiation was 19–61 days (median, 43 days). The mean 
re-irradiation GTV dose was 61.63–77.44  Gy (median, 
69.23 Gy), with a median recurrent volume of 43.81 cm3 
(range, 2.98–197.99  cm3). During follow-up, 77 patients 
(37.7%) were diagnosed with nasopharyngeal necrosis; 
of these, 51 had died. Of those patients who had died, 31 
(60.8%) died of intractable epistaxis, which was deter-
mined to be LNN; 6 (11.8%) died of distant metastasis; 
11 (21.5%) died of local–regional recurrence; and 3 (5.9%) 
died of sequelae, such as difficulty in feeding, encephalat-
rophy, and other medical complications. Cutoff points of 
the continuous variables were analyzed based on LNN; 
the distribution of patients according to the cutoff points 
is shown in Table  1. The respective manifestations of 
nasopharyngeal necrosis on MRI, pathologic examina-
tion, and endoscopy are shown in Figs. 1, 2 and 3.
Univariate logistic regression analysis
Clinical characteristics, including sex, age, BMI at recur-
rence, recurrent stage, interval of recurrence, concur-
rent chemotherapy during re-irradiation, necrosis before 
re-irradiation, initial total radiation dose and fraction-
ated dose, re-irradiation prescription dose to the GTV, 
mean re-irradiation dose, re-irradiation fractionated 
dose, duration of re-irradiation, accumulated total pre-
scription dose to the GTV, and recurrent tumor volume, 
were subjected to univariate logistic regression analy-
sis to determine their associations with LNN. Binary 
univariate regression analysis showed that female sex 
(OR 3.308; 95% CI 1.468–7.454; P  =  0.004), necrosis 
before re-irradiation (OR 3.136; 95% CI 1.374–7.160; 
P  =  0.007), mean re-irradiation dose  ≥71.97  Gy (OR 
2.481; 95% CI 1.118–5.509; P = 0.026), accumulated total 
GTV dose ≥145.50  Gy (OR 3.220; 95% CI 1.108–9.357; 
P = 0.032), and recurrent tumor volume ≥25.38 cm3 (OR 
4.467; 95% CI 1.30–15.322; P  =  0.017) were associated 
with LNN (Table 2).
Multivariate regression analysis and the predictive model
To determine the independent risk factors for LNN, 
the five factors that were statistically significant were 
included in the multivariate regression analysis model 
with Enter method. Sex (AOR 3.354; 95% CI 1.367–8.231; 
P  =  0.008), necrosis before re-irradiation (AOR 3.469; 
95% CI 1.382–8.710; P = 0.008), accumulated total GTV 
dose (AOR 3.763; 95% CI 1.041–13.611; P = 0.043), and 
recurrent tumor volume (AOR 6.063; 95% CI 1.561–
23.543; P = 0.009) were the independent risk factors for 
LNN (Table  2). The corresponding regression equation 
was as below:
 Note: X1 =  sex (men =  0; women =  1); X2 = necrosis 
before re-irradiation (no = 0; yes = 1); X3 =  total GTV 
dose (<141.50 Gy = 0; ≥141.50 Gy = 1); and X4 = recur-
rent volume (<25.38  cm3  =  0;  ≥25.38  cm3  =  1 ). 
Logitπ  =  ln (π/1  −  π); π means the risk of developing 
LNN of corresponding logit value.
The logitπ value for each patient was calculated 
according to the scoring model and graded quarterly by 
Logitpi = 1.229X1 + 1.276 X2 + 1.548X3 + 1.827X4 − 4.072
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the corresponding estimated risk of developing LNN 
(Table 3). The probability of patients with logitπ ≥1.099 
developing LNN was over 75% after re-irradiation with 
radical IMRT. However, the probability of developing 
LNN was less than 25% when logitπ  <−1.099. In this 
study, 12 patients were assigned to the high-risk group 
which was defined as risk degree IV, and seven patients 
actually developed LNN (Table 3).
Discussion
In the present study, for patients with NPC who were 
treated with radical IMRT, we found that sex, necrosis 
before re-irradiation, accumulated total prescription dose 
to the GTV, and recurrent tumor volume are risk factors 
for LNN. We therefore constructed a feasible prognostic 
model that included these factors to predict the risk of 
developing LNN.
IMRT has been proven to improve tumor control and 
decrease acute and late toxicities when compared with 
conventional radiation technology [7, 8, 10, 20–22]. 
However, some severe late toxicities of IMRT, especially 
LNN, have adversely affected patients’ quality of life and 
survival. According to previous studies, 11%–32% of 
NPC patients with severe late adverse events underwent 
re-irradiation with IMRT, which resulted in nasopharyn-
geal necrosis [9, 15, 21]. Even worse, approximately 45% 
of nasopharyngeal necrosis later involved the internal 
carotid artery and resulted in LNN [22]. Hemostasis by 
gelatin sponge compression and nasopharyngeal pack-
ing through the anterior and/or posterior nares are the 
standard therapies. Internal/external carotid artery liga-
tion, stent implantation, and other surgery treatments are 
applied when necessary [23–27]. Unfortunately, the cure 
rate remains very low despite the hemostasis. It is urgent 
to identify re-irradiated NPC patients who are at high 
risk of developing LNN.
Many studies cited dosage as an important risk factor 
for the severity of necrosis [13–15, 17, 19, 23]. Bedwinek 
et  al. [19] reported that osteonecrosis occurred in 9% 
of patients with oral carcinoma and NPC who received 
radiotherapy if the dose was more than 70  Gy. Simi-
larly, Mark et al. [17] observed that 22% of patients who 
received a dose greater than 75  Gy experienced osteo-
radionecrosis. In their study, 28 patients (18.4%) experi-
enced nasopharyngeal necrosis after initial irradiation 
with a dose over 70 Gy. However, the incidence was much 
higher for re-irradiated patients. Hua et al. [15] reported 
that 14 of 28 (50%) patients developed nasopharyngeal 
necrosis after re-irradiation with an accumulated pre-
scription dose over 120 Gy. In our study, univariate anal-
ysis showed that both the accumulated prescription dose 
to the GTV and the mean re-irradiation dose were statis-
tically related to LNN, and multivariate analysis showed 
Table 1 Characteristics of  204 patients with  locally recur-
rent nasopharyngeal carcinoma
All values are presented as the number of patients followed by percentage in 
the parentheses
LNN lethal nasopharyngeal necrosis, CCRT concurrent chemoradiotherapy, GTV 
gross tumor volume, BMI body mass index
Characteristic All (n = 204) LNN (n = 31) Non-LNN (n = 173)
Sex
 Men 160 (78.4) 18 (58.1) 142 (82.1)
 Women 44 (21.6) 13 (41.9) 31 (17.9)
Age (years)
 <39.5 48 (23.5) 4 (12.9) 44 (25.4)
 ≥39.5 156 (76.5) 27 (87.1) 129 (74.6)
Initial radiation dose (Gy)
 <74.68 178 (87.3) 25 (80.6) 153 (88.4)
 ≥74.68 26 (12.7) 6 (19.4) 20 (11.6)
Recurrent stage
 I 13 (6.4) 0 (0) 13 (7.5)
 II 25 (12.3) 4 (12.9) 21 (12.1)
 III 78 (38.2) 13 (41.9) 65 (37.6)
 IV 88 (43.1) 14 (45.2) 74 (42.8)
Interval of recurrence (months)
 <25.5 73 (35.8) 9 (29.0) 64 (37.0)
 ≥25.5 131 (64.2) 22 (72.0) 109 (63.0)
CCRT during re‑irradiation
 Yes 67 (32.8) 8 (25.8) 59 (34.1)
 No 137 (67.2) 23 (74.2) 114 (65.9)
Necrosis before re‑irradiation
 Yes 41 (20.1) 12 (38.7) 29 (16.8)
 No 163 (79.9) 19 (61.3) 144 (83.2)
Re‑irradiation dose (Gy)
 <67 135 (66.2) 18 (58.1) 117 (67.6)
 ≥67 69 (33.8) 13 (41.9) 56 (32.4)
Mean re‑irradiation dose (Gy)
 <71.97 152 (74.5) 18 (58.1) 134 (77.5)
 ≥71.97 52 (25.5) 13 (41.9) 39 (22.5)
Re‑irradiation fractionated dose (Gy)
 <2.3 197 (96.6) 30 (96.8) 167 (96.5)
 ≥2.3 7 (3.4) 1 (3.2) 6 (3.5)
Duration of re‑irradiation (days)
 <49.5 173 (84.8) 23 (74.2) 150 (86.7)
 ≥49.5 31 (15.2) 8 (25.8) 23 (13.3)
Accumulated total GTV dose (Gy)
 <141.5 186 (91.2) 25 (80.6) 161 (93.1)
 ≥141.5 18 (8.8) 6 (19.4) 12 (6.9)
Recurrent tumor volume (cm3)
 <25.38 59 (28.9) 3 (9.7) 56 (32.4)
 ≥25.38 145 (71.1) 28 (90.3) 117 (67.6)
BMI
 <19.8 50 (24.5) 6 (19.4) 44 (25.4)
 ≥19.8 154 (75.5) 25 (80.6) 129 (74.6)
Necrosis
 Yes 77 (37.7) 31 (100) 46 (26.6)
 No 127 (62.2) 0 (0) 127 (73.4)
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that the accumulated prescription dose to the GTV was 
an independent risk factor for LNN. Additionally, large 
recurrent tumor volume is usually considered one of the 
independent factors of poor survival in recurrent NPC 
[28]. Han et al. [10] showed that the OS of NPC patients 
with small recurrent tumor volume (≤38  cm3) was 1.6 
times longer than that of patients with larger recur-
rent tumor volume (>38  cm3) when treated with IMRT. 
Moreover, Hua et al. [11] found that the recurrent tumor 
volume >42 cm3 was an independent predictor of OS in 
patients with locally recurrent NPC who were re-irradi-
ated with IMRT. In our study, we found that a recurrent 
tumor volume ≥25.38 cm3 was an independent prognos-
tic factor for LNN; this tumor volume was much lower 
than those in previous reports discussing survival status, 
suggesting that re-irradiation of large recurrent tumors 
should be administered with caution. Re-irradiation 
is usually the last chance for cure after a patient’s first 
relapse; therefore, for patients at high risk of developing 
LNN, decreasing the re-irradiation dose or the recur-
rent tumor volume might be feasible methods to prevent 
LNN. Considering that reducing the re-irradiation dose 
would likely result in worse control of NPC recurrence, 
administering neoadjuvant chemotherapy to decrease 
the tumor volume may lower the risk of developing LNN 
and improve the local control rate and the survival rate 
[29, 30]. Future clinical trials combining chemother-
apy, molecular targeted therapy, and radiotherapy are 
expected to determine the optimal re-irradiation dose for 
patients with recurrent NPC.
A generally accepted mechanism of injury after irra-
diation is a hypovascular–hypoxic–hypocellular condi-
tion that causes the breakdown of local tissue, exposing 
bone, and the formation of sequestra [31]. The inflam-
mation caused by this non-healing wound may, in turn, 
increase the demand of the local tissue for energy, oxy-
gen, and other metabolites, which may lead to more seri-
ous collagen destruction and cell death [17]. This is a 
Fig. 1 Magnetic resonance imaging of nasopharyngeal necrosis. a Coronal, contrast‑enhanced, T1‑weighted image shows non‑enhanced soft tis‑
sues (like a hole) mixed with tiny air bubbles in the left nasopharyngeal lateral recess (arrow). b Transverse, contrast‑enhanced, T1‑weighted image 
shows the necrotic extent in the nasopharyngeal posterior wall (arrow). c Sagittal, contrast‑enhanced, T1‑weighted image shows an obvious defect 
in the left nasopharyngeal lateral recess (arrow)
Fig. 2 Pathologic characteristics of nasopharyngeal necrosis. The three necrotic tissues (a–c) were taken from three NPC patients. Hematoxylin–
eosin staining of nasopharyngeal necrosis is similar that shows many red-stained substances without cellular structure (arrows)
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reasonable explanation for our findings. We found that 
necrosis before re-irradiation was an independent risk 
factor for LNN. Of the 41 patients with nasopharyngeal 
necrosis after the first irradiation, 12 (29.3%) progressed 
to LNN after re-irradiation with IMRT. Re-irradiation 
aggravated injuries caused by the first irradiation, which 
increased oxygen demand in these aggravated areas. At 
the same time, previous repair processes, such as fibro-
sis, may also constrain the local blood supply, which can 
hinder the healing of necrosis after re-irradiation. As 
previously reported, weekly debridement and excision of 
necrotic tissue under nasopharyngeal endoscopy, daily 
Table 2 Univariate and multivariate regression analysis on the association between patient characteristics and LNN
LNN lethal nasopharyngeal necrosis, CI, confidence interval, CCT concurrent chemoradiotherapy, GTV gross tumor volume, BMI body mass index, OR odds ratio, AOR 
adjusted odds ratio
Variable Univariate analysis Multivariate analysis
OR 95% CI P AOR 95% CI P
Sex (women vs. men) 3.308 1.468–7.454 0.004 3.354 1.367–8.231 0.008
Age (≥39.5 vs. <39.5 years) 2.302 0.763–6.947 0.139 – – –
Initial radiation dose (≥74.68 vs. <74.68 Gy) 1.836 0.672–5.018 0.236 – – –
Recurrent stage (I vs. II vs. III vs. IV) – – 0.999 – – –
Interval of recurrence (≥25.5 vs. <25.5 months) 1.435 0.623–3.207 0.396 – – –
CCT during re‑irradiation (yes vs. no) 0.672 0.283–1.594 0.367 – – –
Necrosis before re‑irradiation (yes vs. no) 3.136 1.374–7.160 0.007 3.469 1.382–8.710 0.008
Re‑irradiation GTV dose (≥ 67 vs. < 67 Gy) 1.509 0.691–3.296 0.302 – – –
Mean re‑irradiation dose (≥71.97 vs. < 71.97 Gy) 2.481 1.118–5.509 0.026 1.713 0.691–4.248 0.246
Re‑irradiation fractionated dose (≥ 2.3 vs. < 2.3 Gy) – – 0.999 – – –
Duration of re‑irradiation (≥ 49.5 vs. < 49.5 days) 2.268 0.907–5.672 0.08 – – –
Accumulated total GTV dose (≥141.5 vs. <141.5 Gy) 3.220 1.108–9.357 0.032 3.763 1.041–13.611 0.043
Recurrent tumor volume (≥25.38 vs. <25.38 cm3) 4.467 1.302–15.322 0.017 6.063 1.561–23.543 0.009
BMI (≥19.8 vs. <19.8) 1.421 0.547–3.691 0.470 – – –
Fig. 3 Endoscopic examination of nasopharyngeal necrosis. Nasopharyngeal necrosis is shown under endoscopic examination (arrows). a The 
necrosis is located in the roof, posterior, and left wall with obvious mucosa ulcer. Sequestra and necrotic bones can also be seen in the nasopharyn‑
geal cavity. b The nasopharyngeal cavity is covered with yellow to black purulent secretion with necrosis located in the roof, posterior, and right 
lateral wall of the nasopharynx
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nasopharyngeal irrigation, intravenous nutrition, and 
systematic antibiotic therapy can improve some cases to 
a certain extent [15], which may diminish the need for 
procedures to treat nasopharyngeal necrosis. Thus, once 
nasopharyngeal necrosis is diagnosed, timely and effec-
tive treatment is necessary.
Finally, we found that women were more likely than 
men to develop LNN, suggesting that intrinsic biological 
traits, such as sensitivity to radiation, repair ability, and 
hormone levels, may contribute to a patient’s likelihood 
of developing LNN. Future investigations should study 
the relationship between necrosis and sex.
This study had several limitations. First, quick and 
effective measures are very important for hemorrhage 
rescue, but treatments of massive nasopharyngeal bleed-
ing varied considering expense, distance, and clinical 
medical condition. Massive nasopharyngeal bleeding 
involving the internal maxillary artery could be rescued 
with effective treatment, such as hemostasis by gelatin 
sponge compression, nasopharyngeal packing, artery 
ligation, and other surgical measures [32]. However, 
carotid artery rupture is a common result of LNN, which 
results in a high mortality [15]. In this study, we could not 
analyze ruptured arteries because of insufficient clini-
cal data. Second, this study had a relatively small patient 
population, which diminishes the relevance of the results. 
Last, as a retrospective study, the patient population’s 
clinical characteristics were diverse; therefore, an obser-
vational prospective study is necessary to validate this 
scoring system.
Conclusions
For patients with NPC who underwent radical re-irra-
diation with IMRT, we devised a model, which includes 
sex, necrosis before re-irradiation, accumulated total 
prescription dose to the GTV, and recurrent tumor vol-
ume, which can effectively predict the risk of developing 
LNN. We expect that future investigations will suggest 
strategies to prevent or reverse the development of 
LNN.
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